Powder: -20°C for 3 years
In solvent: -80°C for 2 years
Ezatiostat is a tripeptide analog of glutathione that can selectively inhibit GSTP1-1 catalytic activity.
Description | Ezatiostat is a tripeptide analog of glutathione that can selectively inhibit GSTP1-1 catalytic activity. |
In vivo | Ezatiostat was administered to 19 patients with non-deletion(5q) myelodysplastic syndrome (MDS) at one of two doses (2000 mg or 2500 mg/day) in combination with 10 mg of lenalidomide on days 1-21 of a 28-day cycle. One of 4 evaluable patients (25%) in the 2500/10 mg dose group experienced an erythroid hematologic improvement (HI-E) response by 2006 MDS International Working Group (IWG) criteria. Four of 10 evaluable patients (40%) in the 2000 mg/10 mg dose group experienced a HI-E response [1]. Systemic inhibition of GSTP1 with Ezatiostat (0-30 mg/kg, i.p.) dose-dependently reduced the reinforcing effects of alcohol as measured by operant self-administration, in the absence of motor effects [2]. |
Synonyms | TLK199, TER199(free base) |
Molecular Weight | 529.65 |
Formula | C27H35N3O6S |
CAS No. | 168682-53-9 |
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
H2O: Insoluble
DMSO: >50 mg/mL (94.4 mM)
Ethanol: 20 mg/mL (37.76)
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Ezatiostat 168682-53-9 代谢 凋亡 氧化还原 Apoptosis Glutathione Peroxidase GST Inhibitor lymphocyte inhibit TLK 199 TLK-199 Glutathione transferases GSTs Gutathione S-transferase proliferation c-Jun JNK GSTP1 ERK1 TLK199 MDS tripeptide TER199(free base) inhibitor